DeepMind

Develops artificial general intelligence systems

London, England, United Kingdom

About DeepMind

This company leads in the field of artificial general intelligence (AGI), with notable applications across healthcare, energy management, and biotechnology. Their work in early diagnostic tools for eye diseases, optimizing energy usage in major data centers, and groundbreaking contributions to protein structure prediction underlines their commitment to harnessing AI for diverse practical applications. The company's dedication to pushing the boundaries of AI technology not only propels the industry forward but also creates a dynamic and impactful working environment for its employees.

London, United KingdomHeadquarters
2010Year Founded
$4.9MTotal Funding
ACQUISITIONCompany Stage
AI & Machine Learning, BiotechnologyIndustries
1,001-5,000Employees

Benefits

Performance Bonus

Risks

Emerging AI models may challenge DeepMind's current strategies.
Backlash against AI models like Gemini poses reputational risks.
Labeling AI-generated content could increase operational complexity for DeepMind.

Differentiation

DeepMind combines AI, ML, and neuroscience for general-purpose learning algorithms.
DeepMind's AlphaFold model advances protein folding research significantly.
GraphCast by DeepMind offers rapid, accurate ten-day weather forecasts.

Upsides

AI-driven drug discovery is set to grow significantly in 2024.
AlphaCode 2 showcases AI's potential in competitive programming.
DeepMind's AI tools are transforming music creation and meteorology.

Funding

Total raised$4.86 M
Latest valuation$400.00 M
StageACQUISITION
ACQUISITION
12/31/2013
$528
$400.00 M
ANGEL
12/31/2011
$5
$25.00 M